

# TANDEM DIABETES CARE INC

## **FORM 8-K** (Current report filing)

Filed 12/19/17 for the Period Ending 12/15/17

Address	11045 ROSELLE STREET SUITE 200 San Diego, CA, 92121
Telephone	858-366-6900
CIK	0001438133
Symbol	TNDM
SIC Code	3841 - Surgical and Medical Instruments and Apparatus
Industry	Medical Equipment, Supplies & Distribution
Sector	Healthcare
Fiscal Year	12/31

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): December 15, 2017**

---

**Tandem Diabetes Care, Inc.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-36189**  
(Commission  
File Number)

**20-4327508**  
(I.R.S. Employer  
Identification No.)

**11075 Roselle Street,**  
**San Diego, CA**  
(Address of principal executive offices)

**92121**  
(Zip Code)

**Registrant's telephone number, including area code: (858) 366-6900**

**N/A**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

As previously reported by Tandem Diabetes Care, Inc. (the “Company”) in a Current Report on Form 8-K filed on December 7, 2017, Leigh Vosseller, who is currently serving as the Company’s Senior Vice President of Finance, will be appointed as the Company’s Senior Vice President and Chief Financial Officer effective January 1, 2018.

On December 15, 2017, the Compensation Committee of the Board of Directors of the Company (the “Committee”) approved an increase in the base salary to be received by Ms. Vosseller for fiscal year 2018 to \$345,000, effective on January 1, 2018. In addition, the Committee approved (i) a target cash bonus percentage in an amount equal to 40% of Ms. Vosseller’s base salary for fiscal year 2017 (to be applied to the full year), and (ii) a target cash bonus percentage in an amount equal to 50% of Ms. Vosseller’s base salary for fiscal year 2018, with the actual cash bonus amounts for each of fiscal years 2017 and 2018, if any, to be determined at the discretion of the Committee.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tandem Diabetes Care, Inc.

By: /s/ David B. Berger

David B. Berger

Executive Vice President, General Counsel and Secretary

Date: December 19, 2017